Advagene Biopharma Co. Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan.
Advagene Biopharma Co. Ltd. - Asset Resilience Ratio
Advagene Biopharma Co. Ltd. (6709) has an Asset Resilience Ratio of 75.79% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Advagene Biopharma Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Advagene Biopharma Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$149.50 Million | 75.79% |
| Total Liquid Assets | NT$149.50 Million | 75.79% |
Asset Resilience Insights
- Very High Liquidity: Advagene Biopharma Co. Ltd. maintains exceptional liquid asset reserves at 75.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Advagene Biopharma Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Advagene Biopharma Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF |
Biotechnology | 25.67% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Exicure Inc
NASDAQ:XCUR |
Biotechnology | 0.00% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Advagene Biopharma Co. Ltd. (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Advagene Biopharma Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 64.38% | NT$149.50 Million | NT$232.21 Million | +23.82pp |
| 2023-12-31 | 40.56% | NT$60.00 Million | NT$147.93 Million | -19.79pp |
| 2022-12-31 | 60.35% | NT$85.00 Million | NT$140.84 Million | -20.10pp |
| 2021-12-31 | 80.45% | NT$209.50 Million | NT$260.41 Million | +32.51pp |
| 2020-12-31 | 47.94% | NT$151.60 Million | NT$316.26 Million | -14.67pp |
| 2019-12-31 | 62.60% | NT$174.80 Million | NT$279.22 Million | -24.37pp |
| 2018-12-31 | 86.98% | NT$312.04 Million | NT$358.77 Million | +15.54pp |
| 2017-12-31 | 71.43% | NT$161.60 Million | NT$226.23 Million | -- |